Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Beijing Stock Exchange To Roll Out Red Carpet For First Vaccine Firm's Debut

Executive Summary

Chinese vaccine developer Beijing Health Guard Biotechnology is seeking to go public on the newly minted Beijing Stock Exchange, against a backdrop of very few biotechs having tried this route to reach public investors.

You may also be interested in...



Six Chinese Biotechs Bag $403m In Fresh Financing Rounds

In immuno-oncology and beyond, Chinese investors are setting their sights on new targets in the biopharma arena.

Full-Life Expands Radiopharmaceutical Reach With $245m Focus-X Buyout

Full-Life’s acquisition of Focus-X came after two other Chinese biotechs leaped into the fray for a leading position in China’s nascent radionuclide therapy market.

China RNA Activation Venture Ractigen Looks To Clinic For Validation

A China returnee CEO has raised roughly $50m for his bioventure that is looking to clinically validate and commercialize an RNA activation platform he co-discovered while working in the US.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145927

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel